Reaction profile
The FDA adverse-event record for facial paralysis
535 FDA reports name facial paralysis, a high-volume reaction in the CVM extract (VeDDRA 1144). Plate stamps and neighbourhood peers follow.
- #619 of 2,481
- by report volume (all reactions)
- 535
- reports citing this reaction
- 9.0%
- death-coded share
- Dog
- most-affected species
Release-over-release change
What changed in the latest FDA data snapshot
PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Facial paralysis has 535 reports now versus 527 in that prior snapshot: 8 more (1.5%).
- Report change
- +8
- Death-coded reports
- +0
- Death-coded share
- −0.1 pts
This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.
Subscribe to Facial paralysis changesFDA AER · VeDDRA plate
Code 1144 VOL-MID
VOL-MID · DEATH-PAR · UPPER-Q · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL
- VOL-MID 535 reports
- DEATH-PAR 9.0%
- UPPER-Q #619/2481
- PHOTO-FINISH Abdominal cavity diso…
- SPECIES-DOG Dog · 476
- DRUG-LEAD Florfenicol + Mom… · 94
- DESK-WIDE 20 breeds
- BOOK-FULL 8/8 fields
Nearest volume peer: Abdominal cavity disorder NOS (±0 reports)
Upper-third report volume drives the scale stamps on this plate; death-coded share and co-report peers follow. Not a clinical diagnosis.
High-volume neighbourhood around Facial paralysis
Upper-third volume poles plus nearest peers, not a full reaction corpus board reprint.
What the FDA AER plate says about Facial paralysis
Signature read: 535 reports place Facial paralysis in the upper third of FDA AER volume (#619 of 2,481). Report volume is upper-third scale: 535 named reports in the openFDA extract. 48 of 535 reports were death-coded (9.0% of named reports, not a population mortality rate). Nearest volume peer: Abdominal cavity disorder NOS (±0 reports). Lead species Dog (476). Lead co-reported drug Florfenicol + Mometasone Furoate + Terbinafine Hydrochloride (94).
Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Florfenicol + Mometasone Furoate + Terbinafine Hydrochloride appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.
Species Most Affected
Breeds Most Affected
Associated Drugs
Nationwide reactions with similar profiles
Two openFDA-derived peer sets for Facial paralysis, both floored at ≥50 reports so the neighborhoods stay in the advertised mass (the volume chart above is the unfloored photo-finish strip).
Similar report volume
Nearest other reactions by FDA report count (535 here).
Similar death-coded share
Nearest other reactions by death-coded share (9.0% here), distinct from the volume row.
What to do with this reaction
- Compare Facial paralysis's report profile against similar reactions nationwide. See similar reactions
- Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
- Browse the full reaction directory to compare report counts across reaction types. All reactions
A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.
Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025
Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →